Lapatinib靶向治疗联合顺铂+卡培他滨化疗方案治疗HER-2阳性乳腺癌伴肺转移的价值分析  

Value analysis of Lapatinib targeted therapy combined with cisplatin and capecitabine chemotherapy in the treatment of HER-2 positive breast cancer with lung metastasis

作　　者：刘畅 LIU Chang(Anshan Cancer Hospital,Anshan 114036,China)

机构地区：[1]鞍山市肿瘤医院,114036

出　　处：《中国现代药物应用》2022年第4期13-16,共4页Chinese Journal of Modern Drug Application

摘　　要：目的观察人表皮生长因子受体2(HER-2)阳性乳腺癌伴肺转移患者应用拉帕替尼(Lapatinib)靶向治疗联合顺铂+卡培他滨化疗方案的效果。方法118例HER-2阳性乳腺癌伴肺转移患者,采用随机数字表法分为观察组和对照组,各59例。对照组给予顺铂+卡培他滨化疗方案治疗,观察组在对照组基础上另予拉帕替尼治疗。对比两组患者临床疗效、远期疗效、肿瘤标志物[糖类抗原153(CA153)、癌胚抗原(CEA)、组织多肽特异抗原(TPS)]及1、2年生存率和毒副反应发生情况。结果观察组患者的客观缓解率(ORR)55.93%、疾病控制率(DCR)79.66%均高于对照组35.59%、62.71%,差异具有统计学意义(P<0.05)。观察组患者的无进展生存期(8.95±1.12)个月、中位生存期(19.65±1.97)个月均长于对照组的(6.67±1.05)、(15.36±1.59)个月,差异具有统计学意义(P<0.05)。治疗前,两组患者的CA153、CEA、TPS对比差异无统计学意义(P>0.05);治疗后,两组患者的CA153、CEA、TPS均低于本组治疗前,且观察组明显低于对照组,差异具有统计学意义(P<0.05)。观察组患者的1、2年生存率分别为84.75%、66.10%,均高于对照组的67.80%、45.76%,差异具有统计学意义(P<0.05)。两组患者血小板减少、肝损伤、脱发、恶心呕吐、手足综合征发生率对比差异无统计学意义(P>0.05)。结论HER-2阳性乳腺癌伴肺转移患者应用拉帕替尼靶向治疗联合顺铂+卡培他滨化疗方案,可提高ORR、DCR、远期生存率,延长无进展生存期与中位生存期,有效降低肿瘤标志物水平,且安全性较好,值得临床应用。Objective To observe the effect of Lapatinib targeted therapy combined with cisplatin and capecitabine chemotherapy in the treatment of human epidermal growth factor receptor 2(HER-2)positive breast cancer with lung metastasis.Methods A total of 118 cases of HER-2 positive breast cancer with lung metastasis were divided into observation group and control group using random numerical table,with 59 cases in each group.The control group was treated with cisplatin+capecitabine chemotherapy regimen,while the observation group was treated with Lapatinib on the basis of the control group.Both groups were compared in terms of clinical efficacy,long-term efficacy,tumor markers[carbohydrate antigen 153(CA153),carcinoembryonic antigen(CEA),tissue peptide-specific antigen(TPS)]and 1-and 2-year survival rates and the occurrence of toxic side effects.Results The objective response rate(ORR)of the observation group was 55.93%,and the disease control rate(DCR)was 79.66%,which were higher than 35.59% and 62.71% of the control group,and the differences were statistically significant(P<0.05).The progression-free survival(8.95±1.12)months and the median survival(19.65±1.97)months of the observation group were longer than(6.67±1.05)and(15.36±1.59)months of the control group,and the differences were statistically significant(P<0.05).Before treatment,there was no statistically significant difference in CA153,CEA and TPS between the two groups(P>0.05).After treatment,the CA153,CEA and TPS of the two groups were lower than those of this group before treatment,and the observation group was significantly lower than the control group,and the difference was statistically significant(P<0.05).The 1-and 2-year survival rates of the observation group were 84.75%and 66.10%,which were higher than 67.80% and 45.76% of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of thrombocytopenia,liver injury,hair loss,nausea and vomiting,and hand-foot syndrome be

关 键 词：人表皮生长因子受体2阳性 乳腺癌 肺转移 卡培他滨 拉帕替尼 化疗方案 

分 类 号：R737.9[医药卫生—肿瘤]